Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glutamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.40 |
| ▸ | GRM8 | O00222 | 2/20 | 0.40 |
| ▸ | GRM6 | O15303 | 2/20 | 0.40 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamine SCHEMBL4298256 | 1.00 | ALOX15 (0.50) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL4412209 | 1.00 | ALOX15 (0.50) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL1675448 | 1.00 | ALOX15 (0.50) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL5800546 | 1.00 | ALOX15 (0.50) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL28774546 | 1.00 | ALOX15 (0.50) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL5307070 | 0.95 | ALOX15 (0.45) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL1675342 | 0.95 | ALOX15 (0.45) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL19031702 | 0.95 | ALOX15 (0.45) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL19031700 | 0.95 | ALOX15 (0.45) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL3442669 | 0.95 | ALOX15 (0.45) | ALOX15BLMPMP22KMT2AGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1064010-A4 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | CONNECTIVE TISSUE IMAGINEERING (US) | 2004-10-06 | — | — | EP | claimed |
| EP-1064010-A1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | Mrs, Llc (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999045941-A1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | MRS, LLC (US) | 1999-09-16 | — | — | WO | claimed |
| CN-116042568-A | Intein Crv Rpb2 variant, coding gene and application thereof in preparation of hexapeptide-nine | 广州市乾相生物科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-3334451-B1 | COMPOSITION FOR THE TREATMENT OF JOINT CONDITIONS | STOFFEL BERNARD (BE) | 2020-10-28 | — | — | EP | disclosed |
| US-20190000874-A1 | Composition for the Treatment of Joint Conditions | NEWVEN SPRL (BE) | 2019-01-03 | — | — | US | disclosed |
| EP-3334451-A1 | COMPOSITION FOR THE TREATMENT OF JOINT CONDITIONS | Stoffel, Bertrand (BE) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017025635-A1 | COMPOSITION FOR THE TREATMENT OF JOINT CONDITIONS | NEWVEN SPRL (BE) | 2017-02-16 | — | — | WO | disclosed |
| US-9458197-B2 | Elastin digest compositions and methods utilizing same | HUMAN MATRIX SCIENCES, LLC (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150110755-A1 | ELASTIN PRODUCING FIBROBLAST FORMULATIONS AND METHODS OF USING THE SAME | NULASTIN, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150004184-A1 | ELASTIN DIGEST COMPOSITIONS AND METHODS UTILIZING SAME | NULASTIN, INC. | 2015-01-01 | — | — | US | disclosed |
| WO-2008148143-A1 | DIAGNOSTICS IN A MONOPLEX/MULTIPLEX FORMAT | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-11 | — | — | WO | disclosed |
| WO-2006081623-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDES AND USES THEREFOR | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2006-08-10 | — | — | WO | disclosed |
| CN-1267149-C | Composition and methods to improve neural outcome | AUCKLAND UNISERVICES LTD (NZ) | 2006-08-02 | — | — | CN | disclosed |
| US-6780848-B2 | Use of GPE to protect glial cells or non-dopaminergic cells from death from neural injury or disease | NeuronZ, Ltd. (NZ) | 2004-08-24 | — | — | US | disclosed |
| US-20020013277-A1 | Composition and methods to improve neural outcome | ENDOCRINZ LIMITED (NZ) | 2002-01-31 | — | — | US | disclosed |
| EP-0735894-A4 | COMPOSITION AND METHODS TO IMPROVE NEURAL OUTCOME | AUCKLAND UNISERVICES LTD (NZ) | 1999-08-18 | — | — | EP | disclosed |
| CN-1142770-A | Composition and methods to improve neural outcome | AUCKLAND UNISERVICES LTD (NZ) | 1997-02-12 | — | — | CN | disclosed |
| EP-0735894-A1 | COMPOSITION AND METHODS TO IMPROVE NEURAL OUTCOME | AUCKLAND UNISERVICES LIMITED (NZ) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995017204-A1 | COMPOSITION AND METHODS TO IMPROVE NEURAL OUTCOME | AUCKLAND UNISERVICES LIMITED (NZ) | 1995-06-29 | — | — | WO | disclosed |